Cover Image
市場調查報告書

Merck & Co., Inc.- 產品平台檢討

Merck & Co., Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253698
出版日期 內容資訊 英文 388 Pages
訂單完成後即時交付
價格
Back to Top
Merck & Co., Inc.- 產品平台檢討 Merck & Co., Inc. - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 388 Pages
簡介

Merck & Co., Inc.是總公司設置於美國,以研究開發為主的全球性醫療保健企業。從事從品牌藥到生技藥品,處方藥,OTC藥,疫苗,消費者照護產品,動物用醫藥品等多元化產品的藥物研發·開發·製造及商業化。

本報告提供Merck & Co., Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Merck & Co., Inc.的基本資料

  • Merck & Co., Inc.概要
  • 主要資訊
  • 企業資料

Merck & Co., Inc.:R&D概要

  • 主要的治療範圍

Merck & Co., Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

Merck & Co., Inc.:開發中產品概況

  • 後期階段產品開發中產品
  • 臨床階段的開發中產品
  • 初期階段的開發中產品
  • 開發階段不明的開發中產品

Merck & Co., Inc.:藥物簡介

  • (ceftolozane sulfate + tazobactam sodium) 41
  • (lamivudine + raltegravir potassium) 43
  • diquafosol tetrasodium 44
  • human papillomavirus (9-valent) vaccine 46
  • omarigliptin 48
  • pembrolizumab 50
  • sugammadex sodium 56
  • tedizolid phosphate 58
  • corifollitropin alfa 60
  • (actoxumab + bezlotoxumab) 62
  • (doravirine + lamivudine + tenofovir disoproxil fumarate) 63
  • (ertugliflozin + metformin) 64
  • (ertugliflozin + sitagliptin) 65
  • (etoricoxib + tizanidine) 66
  • (grazoprevir + elbasvir) 67
  • actoxumab 69
  • anacetrapib 70
  • aprepitant 72
  • asenapine maleate 74
  • bevenopran 75
  • bezlotoxumab 77
  • desloratadine 78
  • doravirine 79
  • fidaxomicin 80
  • insulin glargine 83
  • letermovir 85
  • MK-8237 86
  • MK-8931 88
  • odanacatib 89
  • posaconazole 91
  • rituximab biosimilar 92
  • solithromycin 93
  • surotomycin 95
  • V-212 96
  • V-920 98
  • vibegron 101
  • vorinostat 102
  • BQ-123 106
  • dalotuzumab 108
  • grazoprevir 111
  • lomerizine 113
  • lonafarnib 114
  • mirtazapine ODT 116
  • MK-1029 117
  • MK-2206 118
  • MK-2206 + selumetinib sulfate 121
  • MK-7622 123
  • MK-8342B 124
  • MK-8628 125
  • narlaprevir 127
  • relebactam 128
  • samatasvir 130
  • temozolomide 132
  • V-114 134
  • MK-3682 135
  • CB-618 136
  • MK-0752 137
  • MK-1075 138
  • MK-2048 139
  • MK-2248 140
  • MK-2640 141
  • MK-4166 142
  • MK-7680 143
  • MK-8150 144
  • MK-8189 145
  • MK-8242 146
  • MK-8291 148
  • MK-8408 149
  • MK-8507 150
  • MK-8521 151
  • MK-8591 152
  • MK-8666 153
  • MK-8723 154
  • MK-8876 155
  • Monoclonal Antibody for Autoimmune Diseases 156
  • NB-1008 157
  • SCH-772984 158
  • Small Molecule 1 for Human Cytomegalovirus Infection 159
  • Small Molecule 2 for Human Cytomegalovirus Infection 160
  • V-160 161
  • V-180 162
  • BNC-375 163
  • CB-027 164
  • chikungunya vaccine 165
  • DORA-12 166
  • Drug to Inhibit 11Beta-HSD1 for Hypertension 167
  • Drugs to Inhibit CYP11B2 for Cardiovascular Diseases 168
  • ETP-142 169
  • GP-4 170
  • GRA-1 171
  • J8-CRM197 172
  • M-867 173
  • mDX-400 174
  • MK-4256 175
  • MK-8745 176
  • MK-8825 177
  • MK-8970 178
  • Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia 179
  • MRK-003 180
  • Oligonucleotides for Viral Infections 181
  • OTX-009 182
  • Proteins for Cancer, Autoimmune and Inflammatory diseases 183
  • PTC-512 184
  • PTC-725 185
  • PTC-971 186
  • respiratory syncytial virus vaccine 187
  • SCH-412348 189
  • SCH-546738 190
  • Small Molecule 3 for Human Cytomegalovirus Infection 191
  • Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 192
  • Small Molecule to Inhibit JAK2 for Myeloproliferative Disorder 193
  • Small Molecule to Inhibit Kinesin Spindle Protein for Cancer 194
  • Small Molecule to Inhibit PLK1 for Cancer 195
  • Small Molecules for Atherosclerosis 196
  • Small Molecules to Agonize M1 for Alzheimer's Disease 197
  • Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 199
  • Small Molecules to Block Cav2.2 Channel for Chronic Pain 200
  • Small Molecules to Inhibit DHFR for Septicaemia 201
  • Small Molecules to Inhibit NS5B Polymerase for Hepatitis C 202
  • Small Molecules to Inhibit Prolyl Hydroxylase for Anemia 203
  • THPP-1 204
  • TROX-1 205
  • XEN-445 206
  • XL-499 207
  • Biosimilars for Undisclosed Indication 208
  • Drug to Target GPCR for Undisclosed Indication 209
  • hepatitis C vaccine 210
  • Kibdelomycin A 211
  • Monoclonal Antibodies for Undisclosed Indication 212
  • Monoclonal Antibody for Cancer 213
  • Monoclonal Antibody for Neurology 214
  • SCH-722984 215
  • Small Molecules for Undisclosed Indication 216
  • Small Molecules to Inhibit CGRP Receptor for Migraine 217
  • Small Molecules to Inhibit DGAT1 for Undisclosed Indication 218
  • Small Molecules to Inhibit Renin for Undisclosed Indication 219
  • Small Molecules to Activate sGC for Cardiovascular Disease 220

Merck & Co., Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Merck & Co., Inc.:最新的開發平台資訊

Merck & Co., Inc.:開發暫停中的計劃

Merck & Co., Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Merck & Co., Inc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07997CDB

Summary

Global Markets Direct's, 'Merck & Co., Inc. - Product Pipeline Review - 2016', provides an overview of the Merck & Co., Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Merck & Co., Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Merck & Co., Inc.
  • The report provides overview of Merck & Co., Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Merck & Co., Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Merck & Co., Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Merck & Co., Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Merck & Co., Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Merck & Co., Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Merck & Co., Inc. Snapshot
    • Merck & Co., Inc. Overview
    • Key Information
    • Key Facts
  • Merck & Co., Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Merck & Co., Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Merck & Co., Inc. - Pipeline Products Glance
  • Merck & Co., Inc. - Late Stage Pipeline Products
  • Merck & Co., Inc. - Clinical Stage Pipeline Products
  • Merck & Co., Inc. - Early Stage Pipeline Products
  • Merck & Co., Inc. - Drug Profiles
    • (elbasvir + grazoprevir)
    • asenapine maleate
    • bezlotoxumab
    • desloratadine
    • diquafosol tetrasodium
    • fosaprepitant dimeglumine
    • insulin glargine
    • narlaprevir
    • pembrolizumab
    • (actoxumab + bezlotoxumab)
    • (atorvastatin calcium + ezetimibe)
    • (ceftolozane sulfate + tazobactam sodium)
    • (cilastatin sodium + imipenem + relebactam)
    • (doravirine + lamivudine + tenofovir disoproxil fumarate)
    • actoxumab
    • anacetrapib
    • corifollitropin alfa
    • doravirine
    • fidaxomicin
    • letermovir
    • odanacatib
    • omarigliptin
    • posaconazole
    • solithromycin
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract
    • tedizolid phosphate
    • V-212
    • V-920
    • verubecestat
    • vibegron
    • vorinostat
    • (grazoprevir + MK-3682 + MK-8408)
    • BQ-123
    • dalotuzumab
    • elbasvir + grazoprevir + MK-3682
    • grazoprevir
    • lomerizine
    • lonafarnib
    • mirtazapine ODT
    • MK-1029
    • MK-2206
    • MK-2206 + selumetinib sulfate
    • MK-7622
    • MK-8521
    • MK-8628
    • samatasvir
    • temozolomide
    • V-114
    • MK-3682
    • vorapaxar sulfate
    • CB-618
    • insulin human
    • MK-0752
    • MK-1075
    • MK-1248
    • MK-2048
    • MK-2248
    • MK-4166
    • MK-7680
    • MK-8189
    • MK-8242
    • MK-8291
    • MK-8408
    • MK-8507
    • MK-8591
    • MK-8666
    • MK-8723
    • MK-8876
    • Monoclonal Antibody for Autoimmune Diseases
    • NB-1008
    • rituximab biosimilar
    • Small Molecule 1 for Human Cytomegalovirus Infection
    • Small Molecule 2 for Human Cytomegalovirus Infection
    • V-160
    • V-180
    • BNC-375
    • CB-027
    • chikungunya (viral like particles) vaccine
    • DORA-12
    • Drug to Inhibit 11Beta-HSD1 for Hypertension
    • ETP-142
    • GP-4
    • GRA-1
    • J8-CRM197
    • mDX-400
    • MK-0429
    • MK-1966
    • MK-4256
    • MK-8267
    • MK-8745
    • MK-8825
    • MK-8970
    • Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia
    • Monoclonal Antibody for Cancer
    • MRK-003
    • MRK-1777
    • MRLB-11055
    • Proteins for Cancer, Autoimmune and Inflammatory diseases
    • PTC-512
    • PTC-725
    • PTC-971
    • PyP-1
    • respiratory syncytial virus vaccine
    • SCH-412348
    • SCH-546738
  • Small Molecule 3 for Human Cytomegalovirus Infection
  • Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders
  • Small Molecule to Antagonize Glucagon Receptor for Type 2 Diabetes
  • Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Staphylococcus aureus Infection
  • Small Molecule to Inhibit ROMK for Hypertension and Heart Failure
  • Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis
  • Small Molecules for Undisclosed Indications
  • Small Molecules to Agonize GPR119 for Metabolic Disorders
  • Small Molecules to Agonize M1 for Alzheimer's Disease
  • Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease
  • Small Molecules to Block Cav2.2 Channel for Chronic Pain
  • Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases
  • Small Molecules to Inhibit DGAT1
  • Small Molecules to Inhibit DHFR for Septicaemia
  • Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours
  • Small Molecules to Inhibit Prolyl Hydroxylase for Anemia
  • Small Molecules to Inhibit Renin for Hypertension
  • THPP-1
  • TROX-1
  • XEN-445
  • XL-499
  • Drug to Target GPCR for Undisclosed Indication
  • Kibdelomycin A
  • MK-8133
  • Monoclonal Antibodies for Undisclosed Indication
  • Monoclonal Antibody for Neurology
  • SCH-722984
  • Small Molecules to Antagonize Adenosine 2A receptor for Undisclosed Indication
  • Small Molecules to Inhibit Inositol Phosphorylceramide for Fungal Infections
  • Small Molecules to Inhibit IRAK4 for Inflammatory Diseases
  • Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation
  • Small Molecules to Inhibit NS5A for Hepatitis C
  • Small Molecules to Inhibit PPI for Undisclosed Indication
  • Undisclosed Biosimilars
  • Merck & Co., Inc. - Pipeline Analysis
  • Merck & Co., Inc. - Pipeline Products by Target
  • Merck & Co., Inc. - Pipeline Products by Route of Administration
  • Merck & Co., Inc. - Pipeline Products by Molecule Type
  • Merck & Co., Inc. - Pipeline Products by Mechanism of Action
  • Merck & Co., Inc. - Recent Pipeline Updates
  • Merck & Co., Inc. - Dormant Projects
  • Merck & Co., Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Merck & Co., Inc. - Company Statement
  • Merck & Co., Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Merck & Co., Inc., Key Information
  • Merck & Co., Inc., Key Facts
  • Merck & Co., Inc. - Pipeline by Indication, 2016
  • Merck & Co., Inc. - Pipeline by Stage of Development, 2016
  • Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016
  • Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Merck & Co., Inc. - Partnered Products in Pipeline, 2016
  • Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016
  • Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Merck & Co., Inc. - Pre-Registration, 2016
  • Merck & Co., Inc. - Phase III, 2016
  • Merck & Co., Inc. - Phase II, 2016
  • Merck & Co., Inc. - Phase I, 2016
  • Merck & Co., Inc. - Preclinical, 2016
  • Merck & Co., Inc. - Discovery, 2016
  • Merck & Co., Inc. - Pipeline by Target, 2016
  • Merck & Co., Inc. - Pipeline by Route of Administration, 2016
  • Merck & Co., Inc. - Pipeline by Molecule Type, 2016
  • Merck & Co., Inc. - Pipeline Products by Mechanism of Action, 2016
  • Merck & Co., Inc. - Recent Pipeline Updates, 2016
  • Merck & Co., Inc. - Dormant Developmental Projects,2016
  • Merck & Co., Inc. - Discontinued Pipeline Products, 2016
  • Merck & Co., Inc., Subsidiaries

List of Figures

  • Merck & Co., Inc. - Pipeline by Top 10 Indication, 2016
  • Merck & Co., Inc. - Pipeline by Stage of Development, 2016
  • Merck & Co., Inc. - Monotherapy Products in Pipeline, 2016
  • Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Merck & Co., Inc. - Partnered Products in Pipeline, 2016
  • Merck & Co., Inc. - Out-Licensed Products in Pipeline, 2016
  • Merck & Co., Inc. - Pipeline by Top 10 Target, 2016
  • Merck & Co., Inc. - Pipeline by Top 10 Route of Administration, 2016
  • Merck & Co., Inc. - Pipeline by Top 10 Molecule Type, 2016
  • Merck & Co., Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top